deltatrials
Enrolling By Invitation PHASE4 INTERVENTIONAL 2-arm NCT06800846

Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous and Peri-articular Injection

Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous Multimodal Analgesic Agent Injection Versus Periarticular Injection - A Randomized Control Trial

Sponsor: Thammasat University Hospital

Updated 5 times since 2025 Last updated: Jun 3, 2025 Started: Sep 1, 2024 Primary completion: May 31, 2025 Completion: Jun 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06800846, this PHASE4 trial focuses on Functional Outcomes and Pain Postoperative and remains ongoing. Sponsored by Thammasat University Hospital, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

Intra-operatively, you will be randomly assigned to receive intraosseous multimodal analgesic agent injection or peri-articular multimodal analgesic agent injection along with other standard medications. In the intraosseous injection group: Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation. In the peri-articualr injection group: Participants received combinations of the same drug and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

Intra-operatively, you will be randomly assigned to receive intraosseous multimodal analgesic agent injection or peri-articular multimodal analgesic agent injection along with other standard medications. In the intraosseous injection group: Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation. In the peri-articualr injection group: Participants received combinations of the same drug and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

Status Flow

~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshotEnrolling By Invitation~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshotEnrolling By Invitation~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – present · 9 months · monthly snapshotEnrolling By Invitation~Jan 2026 – present · 3 months · monthly snapshotEnrolling By Invitation

Change History

5 versions recorded
  1. Jan 2026 — Present [monthly]

    Enrolling By Invitation PHASE4

  2. Jul 2025 — Present [monthly]

    Enrolling By Invitation PHASE4

  3. Jun 2025 — Jul 2025 [monthly]

    Enrolling By Invitation PHASE4

  4. Apr 2025 — Jun 2025 [monthly]

    Enrolling By Invitation PHASE4

  5. Feb 2025 — Apr 2025 [monthly]

    Enrolling By Invitation PHASE4

    First recorded

Sep 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Thammasat University Hospital
Data source: Thammasat University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations